Skip to Main Content

INFORMATION FOR

    Announcement

    Nicoli Wins NIH Pioneer Award to Develop a New Kind of mRNA Therapy

    4 Minute Read

    Most of what we know about mRNA fits a single job description: Carry genetic instructions to the cell’s machinery so it can build proteins. That is how mRNA vaccines work, and it is the basis of nearly every mRNA therapy in development.

    But in her research, Stefania Nicoli, PhD, found mRNA doing something else entirely.

    Nicoli, professor of medicine (cardiovascular medicine) and of genetics at Yale School of Medicine, has now received the National Institutes of Health Director’s Pioneer Award to turn that discovery into a new kind of treatment. The award supports researchers with a record of innovation who are pursuing high-risk, high-reward ideas. It provides $700,000 per year for five years.

    “The award is to create a new type of mRNA therapeutic that goes beyond protein synthesis and changes protein behavior,” Nicoli says.

    Uncovering a hidden function of mRNA

    Nicoli studies how cells and tissues adapt when their environment is disturbed, with a focus on the role RNA plays in that response. In 2025, her team uncovered a specialized type of mRNA hidden in inside focal adhesions, large protein complexes that anchor cells to their surroundings and help them move. “They’re essentially the foot of the cell,” Nicoli explains.

    While scientists have studied focal adhesions for decades, no one had noticed this mRNA. What caught Nicoli’s attention was that it was not bound to ribosomes, the machinery that reads mRNA to build proteins. In other words, it was sitting where proteins are needed without making any.

    “From there, we wanted to know what is special about these mRNA and why they’re there without doing their canonical function of making proteins,” Nicoli says.

    To find out, the team removed the mRNA from focal adhesions or swapped in different types. Either change altered how the focal adhesions formed, moved, or broke apart, which in turn changed how well the cells could migrate. The findings showed that mRNA can directly shape how proteins behave, not just whether they are made, expanding the scope of mRNA as a therapeutic.

    A novel mRNA therapeutic

    Today’s mRNA treatments can tell cells to make more of a protein, but they cannot adjust what proteins already present are doing. A molecule that can fine-tune protein behavior could give doctors a new way to steer how cells act.

    With the Pioneer Award, Nicoli’s team will first investigate the molecular structure of the newly discovered mRNA and how it influences protein functions. They will then build synthetic versions and test them as potential drugs.

    Their first target is angiogenesis, the process by which new blood vessels sprout from existing ones. Angiogenesis depends on the movement of endothelial cells, which line the inside of blood vessels. By changing how the focal adhesions in these cells behave, the team hopes to speed up or slow down their migration, and with it the growth of new vessels.

    “I hope to uncover RNA mechanisms that can precisely tune every cell protein behavior and signaling—opening a new way to reprogram cell function and ultimately treat diseases that are currently difficult to cure."

    Stefania Nicoli, PhD, FAHA
    Professor of Medicine and of Genetics

    Tackling incurable diseases and beyond

    Controlling blood vessel growth could help treat several serious conditions, such as diabetic retinopathy, a leading cause of blindness in which abnormal blood vessels grow in the eye and damage the retina. A therapy that blocks those vessels or encourages healthier ones could protect vision.

    The opposite approach could help people with chronic limb-threatening ischemia, an advanced stage of peripheral artery disease in which blockages severely reduce blood flow to the leg or foot. Encouraging new, healthy vessels to grow could help restore that blood flow.

    Further ahead, Nicoli sees possibilities beyond blood vessel disease. She hypothesizes that promoting blood vessel growth in the brain might help slow neurodegeneration, and that blocking cell migration could help prevent cancer from spreading. Those ideas remain in the early stages, but they point to how broadly a tool for controlling focal adhesion protein and all protein behavior might be used.

    “I hope to uncover RNA mechanisms that can precisely tune every cell protein behavior and signaling—opening a new way to reprogram cell function and ultimately treat diseases that are currently difficult to cure,” Nicoli says.

    Article outro

    Author

    Isabella Backman
    Senior Science Writer/Editor, YSM/YM

    Tags

    Media Contact

    For media inquiries, please contact us.

    Explore More

    Featured in this article

    Related News